Mach7 Technologies: Building a solid foundation for FY22

About the author:

Scott Power
Author name:
By Scott Power
Job title:
Senior Analyst
Date posted:
24 August 2021, 7:00 AM
Sectors Covered:
Healthcare, Life Sciences

  • M7T posted an in-line result for FY21. The highlights included a record sales order book and further R&D spend (28% of revenue) into new product development. 
  • Pleasingly, FY22 starts with a revenue base of A$23m which will be added to over the balance of the year, making our A$28m forecast comfortably achievable. M7T also expects to be EBITDA positive for FY22.  
  • We have made immaterial changes to our forecasts which see our DCF based valuation remain at (login to view). The share price has been weak over recent months and we see today’s release as providing confidence to the market that significant revenue growth is ahead in the coming years. Add maintained. 


M7T  posted  a  solid  FY21  result  recording  revenue  of A$19.0m  (in  line  with MorgansF A$19.5m),  the  major  contract  wins  included Trinity  Healthcare  and 
Adventist Healthcare. EBITDA pre-share based payments were A$2.6m and post a loss of A$0.7m (MorgansF loss of A$0.5m).  M7T expensed A$5.4m in new product development. Net loss was A$9.4m (MorgansF a net loss of A$9.4m) assisted by an income tax benefit of A$2.3m. Net operating cash flow was A$1.4m (pcp: A$4.8m), where management had guided to a positive result. M7T finished with cash reserves of A$18.4m. 

Sales orders were the highest on record of A$25.6m (pcp A$13.1m) comprised of 20% subscription base, 72% capital, 8% services only. It was noted that 85% of this order book is yet to be recognised as revenue, setting up a solid base for FY22 and  beyond.  Contracted  annual  recurring  revenue  (CARR)  was  up  43%  to A$15.8m, with ARR at A$13.4m (pcp: A$6.5m).   

Pleasingly, FY22 outlook commentary was detailed which included a base revenue of A$23.1m (made up of A$13.4m in ARR + A$6.1m software licenses already sold, A$2.2m  in  services,  A$1.4m  new  contracts  recognised  in  July).  We  expect additional  contracts  to  be  secured  over  the  balance  of  FY22  and  remain comfortable with our A$28m revenue target. Management also noted that the previously announced revenue target of A$27m for CY21 is on track.


The in-line result is a positive and we note continued R&D spend of A$5.4m to maintain a competitive position in the enterprise imaging market is important. The operating cost base of A$17.5m is expected to edge higher in FY22. 

The guidance for FY22 of positive EBITDA and a revenue base of A$23m which can easily grow to our forecast of ~$28m should be well received by the market. 

Forecast and valuation update

We have made minimal adjustments to what we now believe is a conservative revenue forecast of A$28.0m (was A$27.7m). As we had already rolled our model forward, our DCF based valuation remains unchanged at (login to view).

Investment view

We maintain an Add recommendation. The enterprise imaging sector is forecast to grow from A$2.4bn in 2020 to A$2.9bn in 2025 (CAGR of 3.9%) according to Signify Research Imaging IT World 2021 report. We forecast that M7T’s revenue will achieve 19.2% average compound growth from 2020 to 2025.

Following the eUnity acquisition M7T has a full suite of product which is well placed to service and attract new customers (currently has 165 active customers). 

Price catalysts

Continued contract wins, expansion into new territories and new product development.


The downside risk is delays in securing new contracts due to tight hospital budgets.

Find out more

Download full research note

You can find further detailed analysis of company results this reporting season by browsing our reporting season tag, and view a full list of upcoming results on our Reporting Season Calendar.

If you would like access or more information, please contact your adviser or nearest Morgans office.

Request a call  Find local branch

Need access to our research?

You are also welcome to start a two-week trial of our online platform, which provides access to detailed market analysis and insights, provided by our award-winning research team

Create trial account 

Disclaimer: The information contained in this report is provided to you by Morgans Financial Limited as general advice only, and is made without consideration of an individual's relevant personal circumstances. Morgans Financial Limited ABN 49 010 669 726, its related bodies corporate, directors and officers, employees, authorised representatives and agents (“Morgans”) do not accept any liability for any loss or damage arising from or in connection with any action taken or not taken on the basis of information contained in this report, or for any errors or omissions contained within. It is recommended that any persons who wish to act upon this report consult with their Morgans investment adviser before doing so.

  • Print this page
  • Copy Link